5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F20%3A00536981" target="_blank" >RIV/68378041:_____/20:00536981 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/20:10402394 RIV/00216208:11120/20:43919369 RIV/00216208:11140/20:10402394 RIV/00064190:_____/20:N0000087

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S0163725819301998?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0163725819301998?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pharmthera.2019.107447" target="_blank" >10.1016/j.pharmthera.2019.107447</a>

Jazyk výsledku

angličtina

Název v původním jazyce

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Popis výsledku v původním jazyce

5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several modulation strategies including the implementation of 5-FU-based combination regimens and 5-FU pro-drugs have been developed and tested to increase the anti-tumor activity of 5-FU and to overcome the clinical resistance.nDespite the encouraging progress in CRC therapy to date, the patients response rates to therapy continue to remain low and the patients benefit from 5-FU-based therapy is frequently compromised by the development of chemoresistance. Inter-individual differences in the treatment response in CRC patients may originate in the unique genetic and epigenetic make-up of each individual.nThe critical element in the current trend of personalized medicine is the proper comprehension of causes and mechanisms contributing to the low or lack of sensitivity of tumor tissue to 5-FU-based therapy. The identification and validation of predictive biomarkers for existing 5-FU-based and new targeted therapies for CRC treatment will likely improve patients' outcomes in the future.nHerein we present a comprehensive review summarizing options of CRC treatment and the mechanisms of 5-FU action at the molecular level, including both anabolic' and catabolic ways. The main part of this review comprises the currently known molecular mechanisms underlying the chemoresistance in CRC patients. We also focus on various 5-FU pro-drugs developed to increase the amount of circulating 5-FU and to limit toxicity. Finally, we propose future directions of personalized CRC therapy according to the latest published evidence.

Název v anglickém jazyce

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Popis výsledku anglicky

5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several modulation strategies including the implementation of 5-FU-based combination regimens and 5-FU pro-drugs have been developed and tested to increase the anti-tumor activity of 5-FU and to overcome the clinical resistance.nDespite the encouraging progress in CRC therapy to date, the patients response rates to therapy continue to remain low and the patients benefit from 5-FU-based therapy is frequently compromised by the development of chemoresistance. Inter-individual differences in the treatment response in CRC patients may originate in the unique genetic and epigenetic make-up of each individual.nThe critical element in the current trend of personalized medicine is the proper comprehension of causes and mechanisms contributing to the low or lack of sensitivity of tumor tissue to 5-FU-based therapy. The identification and validation of predictive biomarkers for existing 5-FU-based and new targeted therapies for CRC treatment will likely improve patients' outcomes in the future.nHerein we present a comprehensive review summarizing options of CRC treatment and the mechanisms of 5-FU action at the molecular level, including both anabolic' and catabolic ways. The main part of this review comprises the currently known molecular mechanisms underlying the chemoresistance in CRC patients. We also focus on various 5-FU pro-drugs developed to increase the amount of circulating 5-FU and to limit toxicity. Finally, we propose future directions of personalized CRC therapy according to the latest published evidence.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacology and Therapeutics

ISSN

0163-7258

e-ISSN

—

Svazek periodika

206

Číslo periodika v rámci svazku

feb.

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

19

Strana od-do

107447

Kód UT WoS článku

000509737600009

EID výsledku v databázi Scopus

2-s2.0-85075856144